World journal of clinical oncology最新文献

{"title":"Recent efficacy and long-term survival of <i>Astragalus</i> polysaccharide combined with gemcitabine and S-1 in pancreatic cancer.","authors":"Guang-Yu Li, Jing Jiang","doi":"10.5306/wjco.v15.i11.1404","DOIUrl":"10.5306/wjco.v15.i11.1404","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is a highly malignant tumor with a rapid progression rate and a high susceptibility to infiltration and metastasis. <i>Astragalus</i> polysaccharide (APS), a pure Chinese medicine preparation primarily made from the traditional Chinese herb <i>Astragalus</i>, plays a positive role in the treatment of many malignant tumors.</p><p><strong>Aim: </strong>To explore the recent efficacy of APS combined with gemcitabine plus tegafur gimeracil oteracil potassium capsule (S-1) (GS) regimen in the treatment of pancreatic cancer and assess its effect on the immune function and long-term survival of patients.</p><p><strong>Methods: </strong>A total of 97 patients who were diagnosed with pancreatic cancer and received GS chemotherapy at The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine) from March 2021 to December 2021 were included in the retrospective analysis. Among them, 41 patients received APS combined with GS chemotherapy, and 56 patients received GS chemotherapy only. The recent efficacy, immune function, adverse reactions, and long-term survival were compared among these patients.</p><p><strong>Results: </strong>After 4 cycles of treatment, the objective response rate of patients receiving the combined therapy of APS and GS was 51.22%, and the disease control rate (DCR) was 56.10%, higher than those of patients receiving the monotherapy with GS alone (30.36% and 35.71%, respectively). Besides, the percentages of CD3+ T cells (50.18% ± 9.57%) and CD4+ T cells (31.52% ± 5.33%) in the peripheral blood of patients receiving the combined therapy of APS and GS were higher compared with those treated with GS regimen alone [(44.06% ± 8.55%) and (26.01% ± 7.83%), respectively]. Additionally, the incidences of leukopenia, thrombocytopenia, and fatigue in patients receiving the combined therapy of APS and GS were significantly lower than those in patients receiving the monotherapy of GS alone (17.07%, 9.76%, 31.71% <i>vs</i> 37.50%, 28.57%, 60.71%). Moreover, the median survival time of patients receiving the combined therapy of APS and GS was 394 days, significantly longer than that of patients receiving the monotherapy of GS alone (339 days) (hazard ratio: 0.66; 95%CI: 0.45-0.99; <i>P</i> = 0.036). All these differences were statistically significant (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The combined therapy of APS and GS improved the recent efficacy and long-term survival of patients with pancreatic cancer and alleviated chemotherapy-induced immune suppression and adverse reactions.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1404-1411"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary pancreatic lymphoma: A case report and review of literature.","authors":"Marko M Stojanovic, Vesna Brzacki, Goran Marjanovic, Milica Nestorovic, Jelena Zivadinovic, Miljan Krstic, Marko Gmijovic, Ilija Golubovic, Svetlana Jovanovic, Miroslav P Stojanovic, Katarina Terzic","doi":"10.5306/wjco.v15.i11.1444","DOIUrl":"10.5306/wjco.v15.i11.1444","url":null,"abstract":"<p><strong>Background: </strong>Primary pancreatic lymphoma (PPL) is a rare tumor that mimics pancreatic adenocarcinoma, leading to diagnostic and therapeutic challenges. PPL accounts for 0.2% of all pancreatic tumors and is typically treated with chemotherapy. However, the long-term survival rates for PPL with chemotherapy and radiotherapy alone are unsatisfactory. Due to the improvements in pancreatic surgery, there is a need to reevaluate the treatment strategies for PPL.</p><p><strong>Case summary: </strong>A 62-year-old male presented to our clinic. A biopsy was unsuccessful, and the imaging was suggestive of pancreatic adenocarcinoma. Therefore, subtotal splenopancreatectomy was performed and histopathology was performed. He was then diagnosed with primary pancreatic diffuse large B-cell lymphoma. He received adjuvant chemotherapy and radiotherapy. Currently, the patient is alive with no evidence of disease 36 months after surgery.</p><p><strong>Conclusion: </strong>The potential role of surgery in the treatment of PPL should be emphasized and added in the management protocol of early stage lymphoma.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1444-1453"},"PeriodicalIF":2.6,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation and analysis of the status of cancer health popularization in China, 2023.","authors":"Hai-Tao Hu, Yu-Juan Jiang, Xin-Xin Shao, Yi-Ming Lu, Yan-Tao Tian, Quan Xu","doi":"10.5306/wjco.v15.i10.1269","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1269","url":null,"abstract":"<p><strong>Background: </strong>Cancer presents a significant public health challenge in China, necessitating broad collaboration across society. The Chinese government has articulated a goal to increase the overall five-year survival rate for cancer by 15% by 2030. Achieving this objective requires not only advances in medical technology, but also an improvement in the dissemination of knowledge pertaining to cancer prevention and treatment.</p><p><strong>Aim: </strong>To provide a comprehensive understanding of the status of cancer prevention and level of popularization in China in 2023.</p><p><strong>Methods: </strong>From January 2023 to May 2023, online questionnaires were distributed to 3000 participants, including medical personnel, patients with cancer, their families, and the general public. There were 2711 valid responses, covering the entire nation.</p><p><strong>Results: </strong>A total of 1020 medical personnel and 1691 patients with cancer, their family members, and the general public participated in the survey. Among medical personnel, 93.2% had popularized cancer health. Commonly addressed topics included cancer prevention (85.9%) and cancer screening (77.8%). Primary challenges included time constraints (73.9%), insufficient personnel and material support (66.7%), and uncertainty as to where to begin (49.3%). Among patients with cancer, their family members, and the general public, 93.4% reported reading or watching cancer science popularization materials and 56.9% expressed a desire for deeper understanding. The most sought-after topics in cancer science popularization included cancer screening (80.2%) and cancer prevention (75.8%). The greatest challenge encountered in accessing cancer health popularization was an abundance of misinformation (67.5%).</p><p><strong>Conclusion: </strong>Most clinical doctors, patients, family, and the general public wish to participate in cancer education. However, improvement in the quality of content in cancer prevention and treatment education is required.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1269-1279"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nursing of a patient with multiple primary cancers: A case report and review of literature.","authors":"Di Liu, Sheng-Chao Li","doi":"10.5306/wjco.v15.i10.1315","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1315","url":null,"abstract":"<p><strong>Background: </strong>Although the occurrence of multiple primary cancers (MPC) is not exceedingly common, it is not rare in clinical practice. In recent years, there has been a notable increase in its incidence. The frequent confusion between MPC and tumor metastasis or recurrence often leads to delays in diagnosis and treatment. This study aimed to enhance understanding of MPC, improve diagnostic accuracy, guide precise clinical treatment, and implement a case management nursing model (CMNM) to facilitate quick patient recovery.</p><p><strong>Case summary: </strong>A 61-year-old female patient presented with persistent upper abdominal pain lasting over 2 months. Gastroscopy revealed the presence of both gastric and duodenal cancers. Following a thorough evaluation, the patient underwent pancreaticoduodenectomy, cholecystectomy, and total gastrectomy. Post-surgery, an individualized case management nursing approach was applied, leading to a successful recovery. Three months after the surgery, follow-up examinations showed no signs of recurrence.</p><p><strong>Conclusion: </strong>The CMNM effectively promoted rapid patient recovery, enhanced the quality of orthopedic nursing services, and accelerated postoperative recovery, ultimately leading to increased patient satisfaction with nursing care.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1315-1323"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature.","authors":"Xiao-Qian Li, Jing Yang, Bo Liu, Shu-Mei Han","doi":"10.5306/wjco.v15.i10.1351","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1351","url":null,"abstract":"<p><strong>Background: </strong>In patients with human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer (GC), the combination of HER2 targeting and a standard first-line chemotherapy regimen has been demonstrated to significantly improve their prognosis. However, in a proportion of patients, cancer progresses within a short period of time, and there is currently no standard treatment after disease progression.</p><p><strong>Case summary: </strong>This study presents a case of a 51-year-old male with advanced GC who underwent radical resection (Billroth type II subtotal gastrectomy and gastrojejunostomy) and resection of liver metastases. Immunohistochemical staining revealed a HER2 score of 2+, a dMMR status, and a Ki67 proliferation index of 30% to 40%. The gene test results indicated the presence of ERBB2 amplification and a PD-L1 expression level of less than 5%. Since December 2021, the patient has experienced disease progression during both first-line (two cycles of KN026 combined with KN046) and second-line (five cycles of nivolumab combined with trastuzumab and SOX chemotherapy) treatment regimens. The patient's prognosis following the first and second lines of treatment was unfavorable, with progression occurring in a relatively short time. For third-line therapy, disitamab vedotin (RC48) plus apatinib was used. At the time of this report, the patient had achieved a progression-free survival (PFS) of 25.8 months, which exceeded the median survival time for patients with advanced GC.</p><p><strong>Conclusion: </strong>Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1351-1358"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysbiosis and colonic adenoma: The lethal link?","authors":"Krishna Kumar Govindarajan","doi":"10.5306/wjco.v15.i10.1376","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1376","url":null,"abstract":"<p><p>Gut dysbiosis, a phenomenon in which the existing commensal microbiome changes to an adverse microenvironment in the colon, is thought to lead to altered cellular signals. How this is involved in producing mucosal outgrowths such as polyps in the colon is intriguing. Deciphering the various mechanisms involved provides an in-depth understanding of the link between gut dysbiosis and colonic polyps.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1376-1378"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory and nutritional markers in colorectal cancer: Implications for prognosis and treatment.","authors":"Mesut Tez","doi":"10.5306/wjco.v15.i10.1264","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1264","url":null,"abstract":"<p><p>The prognosis of colorectal cancer (CRC) patients with peritoneal metastasis remains poor despite advancements in detection and treatment. Preoperative inflammatory and nutritional markers have emerged as significant predictors of prognosis in CRC, potentially guiding treatment decisions and improving patient outcomes. This editorial explores the prognostic value of markers such as the neutrophil-to-lymphocyte ratio, hemoglobin, and serum albumin levels. By integrating these markers into prognostic models, clinicians can better stratify patients, personalize treatment strategies, and ultimately enhance clinical outcomes. This review highlights the importance of these markers in providing a comprehensive assessment of patient condition and underscores the need for further research to validate their clinical utility and uncover underlying mechanisms.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1264-1268"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaginal clear cell adenocarcinoma in Herlyn-Werner-Wunderlich syndrome: A case report.","authors":"Xian-Gao Lei, Heng Zhang","doi":"10.5306/wjco.v15.i10.1359","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1359","url":null,"abstract":"<p><strong>Background: </strong>Herlyn-Werner-Wunderlich (HWW) syndrome is a rare Müllerian duct anomaly, characterized by a combination of urogenital abnormalities. The occurrence of primary cervico-vaginal carcinomas in patients with HWW syndrome is exceptionally rare, posing significant challenges for screening, early diagnosis, and effective management.</p><p><strong>Case summary: </strong>We report a rare case of primary clear cell carcinoma of the vagina complicated in a 40-year-old woman with HWW syndrome. The patient presented with irregular vaginal bleeding for 4 years. On gynecological examination, an oblique vaginal septum was suspected. Surgical resection of the vaginal septum revealed a communicating fistula and a tumor on the left vagina and the left side of the septum, which was confirmed as clear cell carcinoma. One month later, she underwent a radical hysterectomy, vaginectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection. Due to significant side effects, she completed only one course of chemotherapy. A year later, lung metastasis was detected and continued to grow. A thoracoscopic wedge resection of the right upper lobe was performed 4 years after the initial surgery. We also conducted a systemic review of the literature on primary cervical or vaginal carcinoma in HWW syndrome to explore this rare entity.</p><p><strong>Conclusion: </strong>Cervico-vaginal adenocarcinomas in patients with HWW syndrome are occult, and require early surgical intervention and regular imaging surveillance.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1359-1365"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot-assisted partial splenectomy for benign splenic tumors: Four case reports.","authors":"Hui-Min Xue, Peng Chen, Xiao-Jun Zhu, Jing-Yi Jiao, Peng Wang","doi":"10.5306/wjco.v15.i10.1366","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1366","url":null,"abstract":"<p><strong>Background: </strong>Robotic-assisted partial splenectomy (RAPS) is a superior approach for treating splenic cysts and splenic hemangiomas, as it preserves the immune function of the spleen and reduces the risk of overwhelming post splenectomy infection. Currently, there are no standardized guidelines for performing a partial splenectomy.</p><p><strong>Case summary: </strong>Four patients with splenic cysts or splenic hemangiomas were treated by RAPS. Critical aspects with RAPS include carefully dissecting the splenic pedicle, accurately identifying and ligating the supplying vessels of the targeted segment, and ensuring precise hemostasis during splenic parenchymal transection. Four successful RAPS cases are presented, where the tumors were removed by pretreating the splenic artery, dissecting and ligating the corresponding segmental vessels of the splenic pedicle, transecting the ischemic segment of the spleen, and using electrocautery for optimal hemostasis. Four patients underwent successful surgeries with minimal bleeding during the procedure, and there were no signs of bleeding or recurrence postoperatively.</p><p><strong>Conclusion: </strong>Four cases confirm the feasibility and superiority of RAPS for the treatment of benign splenic tumors.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1366-1375"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric metastasis of small cell lung carcinoma: A rare but noteworthy entity to consider.","authors":"Cemal Ugur Dursun, Ahmet Oguz Tugcu, Galip Dogukan Dogru","doi":"10.5306/wjco.v15.i10.1379","DOIUrl":"https://doi.org/10.5306/wjco.v15.i10.1379","url":null,"abstract":"<p><p>Small cell lung carcinoma (SCLC) is an aggressive malignancy known for its propensity for early and extensive metastatic spread. Gastric metastasis, where cancer cells disseminate from the lung to the stomach, is a rare but increasingly recognized complication of SCLC. This review provides a comprehensive overview of gastric metastasis in SCLC, addressing its clinical significance, diagnostic challenges, management strategies, and prognosis. Additionally, it examines the broader metastatic patterns of SCLC and compares them with other malignancies known for gastric metastasis. Gastric metastasis in SCLC, though infrequent, is clinically significant and often indicates advanced disease with a poor prognosis. SCLC typically metastasizes to the liver, brain, bones, and adrenal glands, with the stomach being an unusual site. The incidence of gastric metastasis ranges from 1% to 5% in autopsy studies, although this may be underestimated due to diagnostic difficulties and asymptomatic early lesions. Diagnosing gastric metastasis presents several challenges, including the asymptomatic nature of many cases, limitations of conventional imaging techniques, and difficulties in distinguishing metastatic lesions from primary gastric cancer <i>via</i> endoscopy. Histopathological diagnosis requires careful examination to identify SCLC cells through their characteristic small cell morphology and neuroendocrine markers. Management of gastric metastasis in SCLC typically involves a multidisciplinary approach. Systemic therapy, primarily chemotherapy, remains the cornerstone of treatment, with palliative care addressing symptoms and complications. Surgical intervention is usually reserved for specific cases requiring symptomatic relief. The prognosis for patients with gastric metastasis from SCLC is generally poor, reflecting the advanced stage of the disease. Median survival is significantly reduced compared to patients without gastric metastasis. This review emphasizes the need for enhanced awareness and early detection to improve patient outcomes and highlights the importance of ongoing research into better diagnostic and therapeutic strategies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 10","pages":"1379-1382"},"PeriodicalIF":2.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}